Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Fruhwald, S; Pollesello, P; Fruhwald, F.
Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.
Expert Rev Cardiovasc Ther. 2016; 14(12):1335-1347 Doi: 10.1080/14779072.2016.1247694 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Fruhwald Sonja

Co-Autor*innen der Med Uni Graz

Fruhwald Friedrich

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

The later stages of heart failure are characterized by a steady decline in quality of life. Clinical priorities should be to maintain functional capacity and quality of life. In the absence of sufficient organs for transplantation, options include left ventricular assist devices and inotropic support. Areas covered: We examined data published in the last two decades on the use of inotropes and inodilators in advanced heart failure. Expert commentary: In the literature, use of conventional inotropes, including adrenergic agonists and phosphodiesterase inhibitors, appears to be suboptimal for achieving the clinical priorities of late-stage heart failure. Evidence suggests instead that the calcium-sensitizing inodilator levosimendan, administered intermittently, delivers improvements in functional capacity and quality of life and does so with no adverse impact on life expectancy. At a terminal or near-terminal stage of heart failure, the therapeutic philosophy should shift towards meeting patients' existential priorities rather than traditional heart failure-centric targets.

Find related publications in this database (using NLM MeSH Indexing)

Cardiotonic Agents - therapeutic use

Heart Failure - physiopathology

Heart Failure - therapy

Heart-Assist Devices -

Humans -

Hydrazones - therapeutic use

Pyridazines - therapeutic use

Quality of Life -

Simendan -

Find related publications in this database (Keywords)

Heart failure

palliative care

inodilator

levosimendan

quality of life

ethics

kidney function

© Med Uni Graz • Impressum